# Clinical Trials Data ERBB2 - Document 32

# Gastric Cancer Metastasized to the Central Nervous System (CNS)

## Clinical Trial: https://clinicaltrials.gov/study/NCT01456455

"eligibilityCriteria": "Inclusion criteria:\n\n\* in order to be eligible for the study, the diagnosis of gastric cancer and/or lower esophageal cancer must be confirmed histologically. CNS involvement must be confirmed either via independent neuroradiological and/or positive CSF cytology.\n\nExclusion criteria:\n\n\* Patients whose diagnosis is not confirmed upon pathological review or where the CNS involvement cannot be confirmed after neuroradiological review will be excluded from this study.",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "international",

Question:  
Based on the following clinical trial information, would a patient with a ERBB2 gene mutation be eligible for the clinical trial?

Answer:  
This trial information doesn't mention ERBB2 gene status as an inclusion or exclusion criterion. Therefore, having an ERBB2 mutation \*doesn't automatically disqualify\* a patient. Eligibility depends on meeting the other criteria:  
  
\* \*\*Confirmed gastric or lower esophageal cancer diagnosis:\*\* This is essential.  
\* \*\*Confirmed CNS involvement:\*\* Also essential, needing confirmation through imaging or cerebrospinal fluid analysis.  
\* \*\*No conflicting pathology or neuroradiology results:\*\* If the pathology review or neuroradiology doesn't confirm the initial diagnosis or CNS involvement, the patient would be excluded.  
  
So, a patient with an ERBB2 mutation \*could\* be eligible if they also fulfill the other inclusion criteria and don't meet any exclusion criteria.